bioImagene - innovative digital pathology
  • Home
  • » News & Events
  • NEWS & EVENTS
  • CONFERENCES
  • MEDIA COVERAGE >>
  • PRESS RELEASES >>

News & Events

Dec 2010

An Interview with Philippe Nore, International Business Leader Digital Pathology

Convergence of Personalized Healthcare and Digital Pathology

November 2010

More M&As in IVD industry

EMAIL ALERTS

Receive our Free email alerts Sign Up»

ADDITIONAL NEWS

August 23, 2010 Roche Acquires BioImagene, a Leading Provider of Digital Pathology Laboratory Solutions
Full Story»

July 27, 2010 BioImagene Collaborates with America's Best Hospitals, to Advance the Field of Digital Pathology
Full Story»

July 12, 2010 Olympus America Licenses Digital Pathology Patents to BioImagene
Full Story»

 

View Press Release Archive »

  • ABOUT US
    • Overview
    • Quality
  • ABOUT DIGITAL PATHOLOGY
    • Overview
    • Pathology Applications
      • Digitization and Archiving
      • Whole Slide Image Analysis
      • Second Opinions
      • Reporting
      • Quality Control
      • Remote Sign-out
      • Remote Consultations
      • Tumor Boards
      • Remote Frozen Sections
      • Telepathology
      • Pathology Education
    • Enabling Personalized Medicine
    • External Resources
  • PRODUCTS & SOLUTIONS
    • Digital Pathology Solutions
    • Whole Slide Scanner
      • iScan Coreo Au
    • Digital Pathology Application Software
      • Virtuoso
    • Digital Pathology Labs
      • iScan Concerto
      • Digital Pathology Workstation
      • iSlide
    • Request Information
  • SLIDE GALLERY
    • Breast Tissue
    • Prostate Tissue
    • Brain Tissue
    • Hematopathology
  • NEWS & EVENTS
    • Overview
    • Conferences
    • Media Coverage
      • 2010
    • Press Releases
      • 2011
      • 2010
  •  
  •  

Roche | Ventana | Contact | Careers | PathXchange

Ventana test systems are for in vitro diagnostic use for specific clinical applications, and are intended for research use only for other applications

®2012 Ventana Medical Systems, Inc.